Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts EGRX Hot Sheet
Join SI Premium – FREE
Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.93, $0.13 better than the analyst estimate of $0.80. Revenue for the quarter came in at $48.1 million versus the consensus estimate of $45.86 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley cuts Cisco rating, sees pull-forward risk after strong run
- Portillo's Inc. (PTLO) Tops Q3 EPS by 3c; Offers Guidance
- ScanSource (SCSC) Misses Q1 EPS by 25c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
